VistaGen Depreciation vs Net Income Analysis
VTGN Stock | USD 2.42 0.06 2.42% |
VistaGen Therapeutics financial indicator trend analysis is much more than just breaking down VistaGen Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether VistaGen Therapeutics is a good investment. Please check the relationship between VistaGen Therapeutics Depreciation and its Net Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
Depreciation vs Net Income
Depreciation vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of VistaGen Therapeutics Depreciation account and Net Income. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between VistaGen Therapeutics' Depreciation and Net Income is -0.7. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Net Income in the same time period over historical financial statements of VistaGen Therapeutics, assuming nothing else is changed. The correlation between historical values of VistaGen Therapeutics' Depreciation and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of VistaGen Therapeutics are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Depreciation i.e., VistaGen Therapeutics' Depreciation and Net Income go up and down completely randomly.
Correlation Coefficient | -0.7 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Depreciation
Depreciation indicates how much of VistaGen Therapeutics value has been used up. For tax purposes VistaGen Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, VistaGen Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in VistaGen Therapeutics financial statement analysis. It represents the amount of money remaining after all of VistaGen Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from VistaGen Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into VistaGen Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.As of the 13th of December 2024, Issuance Of Capital Stock is likely to grow to about 135.8 M, while Selling General Administrative is likely to drop about 13.4 M.
VistaGen Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
VistaGen Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
VistaGen Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 5.8M | 108.3M | 74.6M | 21.1M | 123.7M | 129.8M | |
Total Current Liabilities | 2.8M | 4.2M | 5.8M | 4.6M | 5.1M | 3.8M | |
Total Stockholder Equity | (5.7M) | 92.0M | 64.7M | 12.1M | 114.3M | 120.0M | |
Net Debt | 2.7M | (99.4M) | (65.1M) | (13.9M) | (117.0M) | (111.2M) | |
Retained Earnings | (201.9M) | (219.8M) | (267.6M) | (326.9M) | (356.2M) | (374.0M) | |
Accounts Payable | 1.8M | 838.3K | 2.8M | 2.5M | 1.5M | 1.4M | |
Cash | 1.4M | 103.1M | 68.1M | 16.6M | 119.2M | 125.1M | |
Cash And Short Term Investments | 1.4M | 103.1M | 68.1M | 16.6M | 119.2M | 125.1M | |
Common Stock Total Equity | 42.8K | 49.3K | 180.8K | 206.7K | 237.7K | 249.6K | |
Common Stock Shares Outstanding | 1.5M | 2.9M | 6.6M | 7.0M | 19.4M | 11.6M | |
Liabilities And Stockholders Equity | 5.8M | 108.3M | 74.6M | 21.1M | 123.7M | 129.8M | |
Other Stockholder Equity | 196.1M | 311.6M | 332.3M | 338.9M | 470.5M | 446.9M | |
Total Liab | 11.5M | 16.3M | 9.9M | 9.0M | 9.4M | 8.3M | |
Total Current Assets | 1.6M | 104.1M | 71.0M | 17.5M | 120.7M | 126.7M | |
Common Stock | 49.3K | 180.8K | 206.7K | 7.3K | 27K | 41.8K | |
Short Long Term Debt Total | 4.1M | 3.7M | 3.0M | 2.7M | 2.1M | 3.1M | |
Property Plant And Equipment Net | 3.8M | 3.6M | 3.1M | 2.8M | 2.3M | 1.2M | |
Non Current Assets Total | 4.2M | 4.2M | 3.6M | 3.6M | 3.0M | 3.1M | |
Non Current Liabilities Total | 8.7M | 12.1M | 4.2M | 4.4M | 4.2M | 4.8M | |
Property Plant And Equipment Gross | 3.8M | 3.6M | 4.3M | 2.8M | 3.5M | 3.7M | |
Short Term Debt | 373.2K | 367.8K | 433.3K | 591K | 1.1M | 1.0M | |
Other Current Liab | 561.5K | 1.6M | 1.3M | 1.5M | 1.7M | 1.1M | |
Non Currrent Assets Other | 402.9K | 576.8K | 569.1K | 814.2K | 726K | 762.3K | |
Other Assets | 402.9K | 576.8K | 569.1K | 814.2K | 936.3K | 983.1K | |
Retained Earnings Total Equity | (181.1M) | (201.9M) | (219.8M) | (267.6M) | (240.8M) | (228.8M) | |
Other Current Assets | 2.7K | 968.6K | 2.9M | 869K | 1.5M | 1.6M | |
Deferred Long Term Liab | 355.1K | 529K | 468.2K | 713.3K | 820.3K | 861.3K | |
Property Plant Equipment | 3.8M | 3.6M | 414.3K | 2.8M | 3.2M | 3.3M | |
Net Tangible Assets | (5.7M) | 92.0M | 64.7M | 12.1M | 13.9M | 18.8M | |
Capital Surpluse | 192.1M | 200.1M | 315.6M | 336.1M | 386.5M | 214.3M | |
Capital Lease Obligations | 4.0M | 3.7M | 3.0M | 2.6M | 2.1M | 1.9M |
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with VistaGen Stock
Moving against VistaGen Stock
0.73 | BMY | Bristol Myers Squibb | PairCorr |
0.71 | ESPR | Esperion Therapeutics | PairCorr |
0.68 | DYAI | Dyadic International | PairCorr |
0.5 | GILD | Gilead Sciences | PairCorr |
0.39 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Revenue Per Share 0.029 | Quarterly Revenue Growth (0.34) | Return On Assets (0.39) | Return On Equity (0.62) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.